R&D channel feed – Endpoints News

R&D channel feed

Hub appeal: AstraZeneca is marshaling 350-plus R&D troops in new South San Francisco campus

9 years ago

Gearing up new partnerships, Boehringer gets an option to buy a new player in oncolytic viruses in $230M deal

9 years ago

Pilot crash crushes little Galectin’s share price after NASH study fails

9 years ago

Porges: Gilead’s hep C bash is winding down and it doesn’t have a cure for the hangover

9 years ago

Shire punts late-stage biosimilars of Humira and Enbrel back to Momenta, Coherus

9 years ago

Cancer biotech upstart grabs $18M round, sets out to master relapsed prostate cancer

9 years ago

Bristol-Myers Squibb brings Opdivo to a joint immuno-oncology program with Nektar’s new T cell amplifier

9 years ago

Amgen hit with a setback as Kyprolis fails a key frontline trial for multiple myeloma

9 years ago

Kite’s groundbreaking CAR-T hits key study goal, heads to the FDA

9 years ago

Array Bio surges on positive results for first stage of melanoma combo PhIII

9 years ago

3 for 3 in PhIII: GW Pharma racing to the FDA after bagging another late-stage epilepsy success

9 years ago

As politicians debate the priority review voucher program, the FDA is rooting for its demise

9 years ago

Lundbeck, Otsuka take the latest hit on Alzheimer’s as PhIII drug flops

9 years ago

Teva gets a mixed bag of PhIII data as it lines up against a (better?) Neurocrine rival for tardive dyskinesia

9 years ago

Gilead scraps a PhII/III study early as drug flops against ulcerative colitis

9 years ago

Biotech unicorn Moderna gambles $110M on a groundbreaking mRNA manufacturing facility, blueprints plant #2

9 years ago

Evotec signs up for a 5-year discovery deal with Bayer focused on chronic kidney disease

9 years ago

Genentech dives into mRNA, betting $310M on BioNTech's personalized cancer vaccine tech

9 years ago

Mast’s sickle cell drug flunks PhIII, eclipsing shares

9 years ago

Pridopidine is still a mess in latest Huntington’s study, but Teva maps PhIII

9 years ago

Teva inks $2.6B deal to buy into Regeneron’s PhIII NGF pain drug

9 years ago

Scoop: J&J confirms that the FDA put AML drug on complete hold

9 years ago

Benitec’s abandoned one-dose hep C “cure” actually had two big problems

9 years ago

Lead vaccine from Vical and Astellas flops in a Phase II herpes study

9 years ago

First page Previous page 318 319 320321322 323 324 Next page Last page